Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cybis 10:25 in chronic back/neck pain
NCT04976738Phase 2Completed
- Sponsor
- Cymra Life Sciences
- Start
- Sep 2021
- Primary completion
- Jun 2022
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Cybis 10:25 in chronic back pain and Cervicalgia, sponsored by Cymra Life Sciences. Primary endpoints: Number of participants with one or more adverse event up to 35 days and Number of participants with one or more serious adverse events up to 35 days. Started Sep 2021; status: completed.
02
Drugs
Cybis 10:25
03
Conditions
chronic back painCervicalgia
Beyond the preview
Go deeper on NCT04976738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04976738.